Treatment of Multiple Sclerosis with Type I Interferons

1996 ◽  
pp. 223-250 ◽  
Author(s):  
Richard A. Rudick ◽  
William Sibley ◽  
Luca Durelli
Keyword(s):  
Multiple Sclerosis ◽  
Type I Interferons ◽  
Type I

scholarly journals Endogenous type I interferons and their regulators in multiple sclerosis

2017 ◽  
Vol 8 ◽  
pp. 17-23
Author(s):  
Yusei Miyazaki ◽  
Masaaki Niino
Keyword(s):  
Multiple Sclerosis ◽  
Type I Interferons ◽  
Type I

scholarly journals Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis

PLoS ONE ◽  
2012 ◽  
Vol 7 (6) ◽  
pp. e35927 ◽  
Author(s):  
Finn Sellebjerg ◽  
Martin Krakauer ◽  
Signe Limborg ◽  
Dan Hesse ◽  
Henrik Lund ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Type I Interferons ◽  
Type I ◽  
Recombinant Type

scholarly journals Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis

1997 ◽  
Vol 149 (1) ◽  
pp. 87-93 ◽  
Author(s):  
Klaus-Peter Wandinger ◽  
Karl Wessel ◽  
Petra Neustock ◽  
Aja Siekhaus ◽  
Holger Kirchner
Keyword(s):  
Multiple Sclerosis ◽  
Interleukin 2 ◽  
Type I Interferons ◽  
Type I

Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a

1999 ◽  
Vol 5 (5) ◽  
pp. 317-322 ◽  
Author(s):  
M W Nortvedt ◽  
T Riise ◽  
K M Myhr ◽  
H I Nyland ◽  
B R Hanestad
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Adverse Events ◽  
Interferon Alfa ◽  
Type I Interferons ◽  
Type I ◽  
Recombinant Interferon ◽  
Multiple Sclerosis Patients ◽  
The Impact

The objective of the study was to examine whether the beneficial effect of treatment of interferon alfa-2a on multiple sclerosis seen by magnetic resonance imaging is reflected in a corresponding improvement in the quality of life (QoL) and to address the impact of adverse events related to this treatment on the QoL. The study was a randomised double-blinded placebo-controlled treatment trial including 97 relapsing-remitting multiple sclerosis patients. Thirty-two patients received 4.5 MIU recombinant interferon alfa-2a, 32 patients received 9.0 MIU recombinant interferon alfa- 2a and 33 patients received placebo treatment for 6 months. All patients were followed up 6 months after end of treatment. QoL was assessed according to the eight scales of the SF-36 Health Survey and measured at baseline, month 3, 6 and 12. The effect found on MRI was not reflected in a corresponding change in the QoL. We found a relationship between the presence of new enhancing lesions and reduced QoL among the placebo patients, whereas this was not found among the patients treated with interferon. The presence of the adverse events fatigue, myalgia, headache and weakness were significantly negatively correlated to several of the QoL dimensions. Conclusively, the treatment with interferon alfa- 2a does not seem to improve the patients' QoL after 6 months of treatment, in spite of a marked effect measured by MRI. The treatment is followed by adverse events that negatively affected the QoL.

scholarly journals Development of Autoimmune Hypothyroidism after Interferon-beta 1a Treatment in Patient with Multiple Sclerosis: A Case Report

2018 ◽  
Vol 19 (2) ◽  
pp. 149
Author(s):  
Md Abdul Awal ◽  
Md Sunny Anam Chowdhury ◽  
Md Hafizur Rahman
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Demyelinating Disease ◽  
Type I Interferons ◽  
Type I ◽  
Interferon Β ◽  
Autoimmune Hypothyroidism ◽  
The Central Nervous System ◽  
Multiple Sclerosis Patients ◽  
Established Treatment

<p>Interferon beta therapy is a well-established treatment of patients suffering from multiple sclerosis, a demyelinating disease of the central nervous system. Since type I interferons have immunomodulatory properties, these cytokines may trigger several autoimmune disorders. In this case, we report the development of autoimmune hypothyroidism in a multiple sclerosis patients receiving interferon-β 1a.</p><p>Bangladesh J. Nuclear Med. 19(2): 149-151, July 2016</p>

Sign in / Sign up

Export Citation Format

Share Document